© 2025 Shane Schaffer. All rights reserved
Shane Schaffer is the visionary co-founder, Chairman, and chief executive officer of Cingulate Therapeutics in Kansas City, Kansas. His company, a Phase 3 clinical-stage biopharmaceutical leader, innovates in developing several branded next-generation pharmaceutical products. These products primarily focus on Attention Deficit/Hyperactivity Disorders (ADHD) and extend to cover therapeutic areas such as anxiety disorders and insomnia.
With a robust background spanning 25 years in the pharmaceutical industry, he excels in drug development and commercialization. His strategic leadership and entrepreneurial prowess are evident across various facets of business operations, including product launches, brand planning, and market development. This establishes him as a prominent figure in the biopharmaceutical and marketing sectors.
He completed his doctoral degree in Pharmacy at the University of Kansas in 1999 and furthered his expertise with a postdoctoral fellowship at Rutgers University's College of Pharmacy. He contributed significantly to Pfizer Worldwide Marketing and Morris Plains during his fellowship. At Pfizer Worldwide Marketing in New York, he assumed the role of Marketing Manager, where he was pivotal in developing pre-launch strategies and launching a Global Communications Intranet to enhance communication between medical and marketing stakeholders.
In Morris Plains, New Jersey, he took on roles as Project Manager and External Research Manager, leading advanced sales training and managing Phase IV Medical Research across all marketed brands. His professional journey is marked by several high-profile managerial positions at Pfizer, Novartis, and Sanofi, where he developed and commercialized multiple billion-dollar brands.
At Novartis, he passionately managed the Ritalin® LA and Focalin™ segments, significantly boosting product awareness and market penetration, which earned him several accolades, including the Novartis Business Excellence Award.
Post-Novartis, at Sanofi Aventis, he was instrumental during the company's merger and joint venture phases, significantly impacting professional promotion and salesforce execution for products like Avapro and Avalide.
Following his tenure at Sanofi-Aventis, he joined M|C Communications in Boston as a Consultant in October 2008, leading business strategies for major pharmaceutical companies. In July 2009, he founded Sabre Scientific Solutions, LLC, offering consulting services to the pharmaceutical and biotechnology sectors.
Driven by his passion for ADHD and related disorders, he established Cingulate Therapeutics in January 2013, focusing on creating advanced drug-delivery technologies to enhance treatment efficacy and reduce patient dependency on medications. Under his leadership, Cingulate has partnered with Indegene to market its innovative oral ADHD medication, CTx-1301, currently in phase-3 trials, with plans to submit a new drug application to the FDA by mid-2025.
Beyond his corporate responsibilities, Shane Schaffer is deeply committed to philanthropic efforts, notably with Folds of Honor Charity, which provides educational scholarships to children affected by the loss or disability of military personnel, reflecting his dedication to impactful societal contributions.